Dr. Keith T. Flaherty,reviews a landmark phase III study investigating ipilimumab in patients with previously treated, unresectable stage III or IV melanoma.
Keith T. Flaherty, MD, reviews a landmark phase III study investigating ipilimumab in patients with previously treated, unresectable stage III or IV melanoma.
Source:http://www.clinicaloptions.com/Oncology
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
No comments:
Post a Comment